Nasdaq smmt.

Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...Summit Therapeutics Inc. Common Stock (SMMT) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK and Cambridge, UK. For more information, please visit https://www.summittxinc.com and follow us on Twitter @summitplc. Contact Summit …Nasdaq 14,241.02 –0.07% Crude Oil 75.26 +0.53% US 10 Yr 100.83 +2,191.72% Euro 1.10 +0.04% Dow Jones 35,333.47 –0.16% Russell 2000 1,801.15

Jun 29, 2023 · Investors eyeing a purchase of Summit Therapeutics Inc (Symbol: SMMT) stock, but cautious about paying the going market price of $2.52/share, might benefit from considering selling puts among the ... Dec 4, 2023 · Avenue Therapeutics Inc (NASDAQ:ATXI)’s Major holders. Insiders own 18.50% of the company shares, while shares held by institutions stand at 9.14% with a share float percentage of 11.21%. Investors are also buoyed by the number of investors in a company, with Avenue Therapeutics Inc having a total of 17 institutions that hold shares in the ...

Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...Web

Dec 1, 2023 · Which Summit Therapeutics insiders have been buying company stock? The following insiders have purchased SMMT shares in the last 24 months: Ankur Dhingra ($217,390.39), Mahkam Zanganeh ($16,772,430.15), Manmeet Singh Soni ($4,999,999.20), and Robert W Duggan ($487,318,100.91). Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...Oxford, UK, and Cambridge, MA, US, 9 July 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that it has demonstrated the potential of its DDS-04 series of new class ...Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...CEO. Website. 2003. 77. Bob Duggan. https://www.summittxinc.com. Summit Therapeutics Inc., a biopharmaceutical company, research and develops primarily oncology therapies in the United States, and the United Kingdom. The company’s product pipeline includes SMT-738, a novel class of precision antibiotics for treatment which is in preclinical ...

Summit Therapeutics Inc. Common Stock (SMMT) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.

Aug 20, 2022 · Those following along with Summit Therapeutics Inc. (NASDAQ:SMMT) will no doubt be intrigued by the recent purchase of shares by Robert Duggan, Co-CEO & Executive Chairman of the company, who ...

Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...Webhá 3 dias ... Home SMMT • NASDAQ. add. Share. Summit Therapeutics Inc. $2.13. After ... NASDAQ. Market news. The Times of Israel. 2 hours ago. Israel-based ...30 de jul. de 2014 ... NASDAQ:SMMT. share_price_up350_53d8a4c7a8864. Shares in drug discovery firm Summit (LON:SUMM) advanced early on Wednesday as it emerged chief ...Summit Therapeutics Inc. (NASDAQ:SMMT) issued its earnings results on Monday, November, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.09. The firm earned $6.12 million during the quarter.OXFORD, England, Aug. 17, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ...Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...

Dec 1, 2023 · Which Summit Therapeutics insiders have been buying company stock? The following insiders have purchased SMMT shares in the last 24 months: Ankur Dhingra ($217,390.39), Mahkam Zanganeh ($16,772,430.15), Manmeet Singh Soni ($4,999,999.20), and Robert W Duggan ($487,318,100.91). Summit Therapeutics Inc. (NASDAQ:SMMT) is a biotechnology company that focuses on developing treatments to target infectious diseases. The firm is headquartered in Cambridge, Massachusetts.WebShares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) were down 3.9% on Friday .The company traded as low as $1.94 and last traded at …Summit Therapeutics Inc. Common Stock (SMMT) Nasdaq Listed. DATA AS OF Nov 26, 2021. 0. Add to Watchlist. Add to Portfolio. SMMT SMMT HISTORICAL DATA. Oxford, UK, and Cambridge, MA, US, 17 July 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it highlighted the potential of its preclinical new class antibiotic, SMT ...Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s Major holders Insiders own 0.04% of the company shares, while shares held by institutions stand at 11.94% with a share float percentage of 11.95%. Investors are also buoyed by the number of investors in a company, with Tonix Pharmaceuticals Holding Corp having a total of 40 …Web

Follow. Menlo Park, California, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today announced the successful closing of its ...

Oxford, UK, and Cambridge, MA, US, 17 July 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it highlighted the potential of its preclinical new class antibiotic, ...Follow. Cambridge, Massachusetts, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Dr. Urte Gayko, PhD, has been appointed to our Board of Directors ...(NASDAQ:SMMT) insiders must be dismayed to see the company's market cap drop to US$1.2b. (Simply Wall St.) May-16-23 01:21PM · Why Shares of Summit ...Cambridge, MA, October 2, 2020 – Summit (NASDAQ: SMMT) today announces that it has entered into a binding agreement with the Company’s Chief Executive Officer and Executive Chairman, Robert W ...Oxford, UK, and Cambridge, MA, US, 18 September 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced the publication of a Personal Perspective entitled “Combating ...Cambridge, Massachusetts, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that it will present the Company’s vision ...Apr 13, 2023 · Summit Therapeutics (NASDAQ:SMMT) is a project of Bob Duggan of Pharmacyclics fame. This is what keeps our hopes in the future of this company alive, even though the company keeps changing so much ... Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ...Simply Wall St. Insider Monkey. Find the latest Summit Therapeutics Inc. (SMMT) stock quote, history, news and other vital information to help you with your stock trading and investing. Fiscal Q3 2023 ended 9/30/23. Reported on 11/7/23. Get the latest Summit Therapeutics Inc (SMMT) real-time quote, historical performance, charts, and other financial information to help you make...

Dec 6, 2022 · Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...

Mar 9, 2023 · Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...

May 22, 2023 · Summit Therapeutics PLC (NASDAQ:SMMT)’s CEO Robert Duggan also bought a 376 million shares of the company during the same month at $1.05 per share. As of May 19, the stock is trading at $1.62. Oxford, UK, and Cambridge, MA, US, 15 January 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that it has received notification that on 14 ...OXFORD, United Kingdom, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular ...CAMBRIDGE, Mass. and OXFORD, United Kingdom, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for ...WebSummit Therapeutics Inc. Common Stock (SMMT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Stock analysis for Summit Therapeutics Inc (SMMT:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Oxford, UK, and Cambridge, MA, US, 17 December 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that Erik Ostrowski will ...Oxford, UK, and Cambridge, MA, US, September 17, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) led by billionaire investor Robert W. Duggan as Executive Chairman, Chief Executive Officer and ...Jun 22, 2022 · Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ... Dhingra was up about 35.7% on the buy at the high point of today's trading session, with SMMT trading as high as $1.43 in trading on Friday. VIDEO: Friday 3/10 Insider Buying Report: UNIT, SMMT

OXFORD, United Kingdom, April 26, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular ...Summit Therapeutics Inc (NASDAQ:SMMT) trade information. Upright in the green during last session for gaining 3.76%, in the last five days SMMT remained trading in the green while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $1.93 price level, adding 5.85% to its value on the day.During the recent session, Summit Therapeutics Inc (NASDAQ:SMMT)’s traded shares were 1.08 million, with the beta value of the company hitting -1.02. At the last check today, the stock’s price was $1.65, reflecting an intraday loss of -9.32% or -$0.18. The 52-week high for the SMMT share is $5.Instagram:https://instagram. 1964 nickle valuewhere can i day trade stocksbest etf brokersleggmason Summit Therapeutics Inc. (NASDAQ:SMMT) is a biotechnology company that focuses on developing treatments to target infectious diseases. The firm is headquartered in Cambridge, Massachusetts.Web best financial magazinenexgen energy stock May 5, 2023 · Shares of Summit Therapeutics ( SMMT 4.93%) were up by 61.4% for the week as of late Friday afternoon, according to data provided by S&P Global Market Intelligence. The healthcare stock, which ... OXFORD, United Kingdom, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular ... marcus limonis Follow. Menlo Park, California, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today announced the successful closing of its ...Cambridge, Massachusetts, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Based on a thorough review of the design and enrollment status of two ongoing blinded Phase III Ri-CoDIFy trials, Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will combine its two blinded pivotal Phase III clinical trials evaluating ridinilazole versus …